JPRN-UMIN000004752已完成2 期
Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC) - JBCRG-11TC
Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 58 人开始时间: 2010年12月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
研究概览
简要总结
Results Clinical response rates at 8-12 and 24 weeks were 71% and 57%, respectively, in group A, and 16% and 56%, respectively, in group B. Conclusions The tailored treatment maintained the favorable clinical response to exemestane alone in responders and improved clinical response in nonresponders.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 65years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) Prior treatment for the breast cancer by chemotherapy or hormone therapy (2) Medication that may affect the sex hormone status (hormone replacement therapy, raloxifene, etc.) (eligible if the last dose was at least two months before) (3) Past history of breast cancer or presence of active multiple cancers (eligible if DCIS is located on the other side) (4) Bilateral breast cancer (if tumors on both sides meet the eligibility criteria, the case is not excluded.) (5) Cases for whom non-hormonal therapies such as surgical therapy, chemotherapy, or antibody therapy are recommended as the first treatment of choice (6) Past history of hypersensitivity to any drug or contrast agent used in this study (7) Cases in which another study drug is given for a disease other than breast cancer (8) Cases in which study participation is considered difficult due to the coexistence of psychosis or psychiatric symptoms (9) Cases considered ineligible by the attending physician for other reasons
研究者
相似试验
已完成
2 期
Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy.(JBCRG-11CPA)ER positive, HER2 negative, Stage II or IIIA [T2-3,N0-2,M0], Primary Postmenopausal Invasive Breast Cancer PatientsJPRN-UMIN000004751Japan Breast Cancer Research Group (JBCRG)59
Unknown
2 期
Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerBreast CancerNCT01170143Fudan University60
已完成
不适用
Pre-operative oral supplementation in colorectal cancer patientsMalignant neoplasm of colonCancerColorectal cancerISRCTN02466810niversity of Manchester (UK)126
撤回
2 期
DCE-MRI PET Bevacizumab Study in Rectal CancerRectal Cancer PatientsNCT01426074Abramson Cancer Center at Penn Medicine
Unknown
不适用
p53 and Response to Preoperative Radiotherapy for T2 and T3Rectal CancerNCT02140723Medical University of Vienna60